Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma (DupiMorph)
A Randomized, Placebo-controlled Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Dupilumab in Localized Scleroderma
Sponsor: University of Cologne
Listed as NCT04200755, this PHASE2 trial focuses on Localized Scleroderma and remains completed. Sponsored by University of Cologne, it has been updated 9 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Nov 2024 — Sep 2025 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Dec 2022 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Nov 2021 — Dec 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Cologne
For direct contact, visit the study record on ClinicalTrials.gov .